{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T21:34:09Z","timestamp":1777584849606,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","oooojournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.oooo.2022.04.048","type":"journal-article","created":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T11:20:53Z","timestamp":1651317653000},"page":"e83-e88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Low-dose naltrexone for treatment of burning mouth syndrome"],"prefix":"10.1016","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1386-5594","authenticated-orcid":false,"given":"Linda","family":"Sangalli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oooo.2022.04.048_bib0001","doi-asserted-by":"crossref","unstructured":"International Classification of Orofacial Pain, 1st edition (ICOP). Cephalalgia.2020;40:129-221.","DOI":"10.1177\/0333102419893823"},{"key":"10.1016\/j.oooo.2022.04.048_bib0002","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1186\/s13063-020-04640-4","article-title":"IMMPACT-recommended outcome measures and tools of assessment in burning mouth syndrome ECTs: an international Dephi survey protocol","volume":"21","author":"Carey","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.oooo.2022.04.048_bib0003","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/03331024211036152","article-title":"A systematic review of treatment for patients with burning mouth syndrome","volume":"42","author":"Tan","year":"2022","journal-title":"Cephalalgia"},{"key":"10.1016\/j.oooo.2022.04.048_bib0004","article-title":"Interventions for treating burning mouth syndrome","volume":"11","author":"McMillan","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.oooo.2022.04.048_bib0005","doi-asserted-by":"crossref","unstructured":"Farag AM, Kuten-Shorrer M, Natto Z, et\u00a0al. WWOM VII: Effectiveness of systemic pharmacotherapeutic interventions in the management of BMS: a systematic review and meta-analysis. Oral Dis. doi:10.1111\/odi.13817. Online ahead of print. Accessed on 1\/26\/2022.","DOI":"10.1111\/odi.13817"},{"key":"10.1016\/j.oooo.2022.04.048_bib0006","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0087-21.2021","article-title":"Reported benefits of low-dose naltrexone appear to be independent of the endogenous opioid system involving proopiomelanocortin neurons and \u03b2-endorphin","volume":"8","author":"Metz","year":"2021","journal-title":"eNeuro"},{"key":"10.1016\/j.oooo.2022.04.048_bib0007","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0026-895X(25)09932-8","article-title":"Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors","volume":"45","author":"Raynor","year":"1994","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.oooo.2022.04.048_bib0008","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2174\/1573397113666170321120329","article-title":"Low dose naltrexone in the treatment of fibromyalgia","volume":"14","author":"Metyas","year":"2018","journal-title":"Curr Rheumatol Rev"},{"key":"10.1016\/j.oooo.2022.04.048_bib0009","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1177\/1352458510366857","article-title":"The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial","volume":"16","author":"Sharafaddinzadeh","year":"2010","journal-title":"Mult Scler"},{"key":"10.1016\/j.oooo.2022.04.048_bib0010","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12967-018-1427-5","article-title":"Low dose Naltrexone for induction of remission in inflammatory bowel disease patients","volume":"16","author":"Lie","year":"2018","journal-title":"J Transl Med"},{"key":"10.1016\/j.oooo.2022.04.048_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.687806","article-title":"Potential therapeutic benefit of low dose naltrexone in myalgic encephalomyelitis\/chronic fatigue syndrome: role of transient receptor potential melastatin 3 ion channels in pathophysiology and treatment","volume":"12","author":"Cabanas","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.oooo.2022.04.048_bib0012","first-page":"94","article-title":"Low-dose naltrexone therapy for psoriasis","volume":"24","author":"Weinstock","year":"2020","journal-title":"Int J Pharmac Comp"},{"key":"10.1016\/j.oooo.2022.04.048_bib0013","first-page":"184","article-title":"Low-dose naltrexone for the treatment of sarcoidosis","volume":"34","author":"Weinstock","year":"2017","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.oooo.2022.04.048_bib0014","article-title":"Low dose naltrexone for induction of remission in Crohn's disease","volume":"4","author":"Parker","year":"2018","journal-title":"Coch Database System Rev"},{"key":"10.1016\/j.oooo.2022.04.048_bib0015","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1097\/j.pain.0000000000000230","article-title":"A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain treatment","volume":"156","author":"Rauck","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.oooo.2022.04.048_bib0016","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamadermatol.2017.2445","article-title":"Low-dose naltrexone treatment of familial benign pemphigus (Hailey-Hailey disease)","volume":"153","author":"Ibrahim","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.oooo.2022.04.048_bib0017","first-page":"207","article-title":"Low-dose naltrexone in the treatment of myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS)","volume":"7","author":"Polo","year":"2019","journal-title":"Fatigue"},{"key":"10.1016\/j.oooo.2022.04.048_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2019.109546","article-title":"Low-dose naltrexone reduces symptoms in stiff-person syndrome","volume":"137","author":"Zappaterra","year":"2020","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.oooo.2022.04.048_bib0019","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/jdv.15457","article-title":"Variable response to low-dose naltrexone in patients with Darier disease: a case series","volume":"33","author":"Boehmer","year":"2019","journal-title":"J Eur Acad Dematol Venereol"},{"key":"10.1016\/j.oooo.2022.04.048_bib0020","first-page":"e4225","article-title":"Sjogren's syndrome: clinical benefits of low-dose naltrexone therapy","volume":"11","author":"Zashin","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.oooo.2022.04.048_bib0021","first-page":"1140","article-title":"Novel treatment using low-dose naltrexone for lichen planopilaris","volume":"16","author":"Strazzulla","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.oooo.2022.04.048_bib0022","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jtos.2020.12.003","article-title":"Low-dose naltrexone is effective and well-tolerated for modulating symptoms in patients with neuropathic corneal pain","volume":"20","author":"Dieckmann","year":"2021","journal-title":"Ocul Surf"},{"key":"10.1016\/j.oooo.2022.04.048_bib0023","first-page":"197","article-title":"Low-dose naltrexone: a new therapy option for complex regional pain syndrome type I patients","volume":"20","author":"Sturn","year":"2016","journal-title":"Int J Pharm Compd"},{"key":"10.1016\/j.oooo.2022.04.048_bib0024","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/1753-0407.13202","article-title":"Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: a randomized, double-blind, active-control, crossover clinical trial","volume":"13","author":"Srinivasan","year":"2021","journal-title":"J Diabetes"},{"key":"10.1016\/j.oooo.2022.04.048_bib0025","first-page":"e01475","volume":"15","author":"Neuman","year":"2021","journal-title":"Utilization of low-dose naltrexone for burning mouth syndrome: a case report. A A Pract"},{"key":"10.1016\/j.oooo.2022.04.048_bib0026","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.tripleo.2011.03.024","article-title":"Shortening the xerostomia inventory","volume":"112","author":"Thomson","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.oooo.2022.04.048_bib0027","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1177\/00220345920710070301","article-title":"Clinical criteria for the diagnosis of salivary gland hypofunction","volume":"71","author":"Navazesh","year":"1992","journal-title":"J Dent Res"},{"key":"10.1016\/j.oooo.2022.04.048_bib0028","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/bjd.13613","article-title":"The prevalence of burning mouth syndrome: a population-based study","volume":"172","author":"Kohorst","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.oooo.2022.04.048_bib0029","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0304-3959(95)00089-B","article-title":"The burning mouth syndrome remains an enigma","volume":"62","author":"Zakrzewska","year":"1995","journal-title":"Pain"},{"key":"10.1016\/j.oooo.2022.04.048_bib0030","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1155\/2003\/654735","article-title":"Burning mouth syndrome and other oral sensory disorders: a unifying hypothesis","volume":"8","author":"Grushka","year":"2003","journal-title":"Pain Res Manag"},{"key":"10.1016\/j.oooo.2022.04.048_bib0031","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0304-3959(02)00052-0","article-title":"Sensory dysfunction in burning mouth syndrome","volume":"99","author":"Forssell","year":"2002","journal-title":"Pain"},{"key":"10.1016\/j.oooo.2022.04.048_bib0032","first-page":"82","article-title":"Low-dose naltrexone (LDN)\u2014review of therapeutic utilization","volume":"6","author":"Toljan","year":"2018","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.oooo.2022.04.048_bib0033","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/1742-2094-9-230","article-title":"Neuronal Toll-like receptor 4 signaling induces brain endothelial activation and neutrophil transmigration in vitro","volume":"9","author":"Leow-Dyke","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.oooo.2022.04.048_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2020.135248","article-title":"Low-dose naltrexone reverses facial mechanical allodynia in a rat model of trigeminal neuroagia","volume":"736","author":"de Oliveira","year":"2020","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.oooo.2022.04.048_bib0035","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1526-4637.2009.00613.x","article-title":"Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study","volume":"10","author":"Younger","year":"2009","journal-title":"Pain Med"},{"key":"10.1016\/j.oooo.2022.04.048_bib0036","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cell.2009.09.028","article-title":"Cellular and molecular mechanisms of pain","volume":"139","author":"Basbaum","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.oooo.2022.04.048_bib0037","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.adaj.2020.08.019","article-title":"Use of low-dose naltrexone in the management of chronic pain conditions. A systematic review","volume":"151","author":"Hatfield","year":"2020","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.oooo.2022.04.048_bib0038","doi-asserted-by":"crossref","first-page":"E118","DOI":"10.1016\/j.brs.2018.12.216","article-title":"Proceedings #47: low dose naltrexone: a viable alternative for long term chronic pain?","volume":"12","author":"Rivera","year":"2019","journal-title":"Brain Stimul"},{"key":"10.1016\/j.oooo.2022.04.048_bib0039","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-232502","article-title":"Low-dose naltrexone as a treatment for chronic fatigue syndrome","volume":"13","author":"Bolton","year":"2020","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.oooo.2022.04.048_bib0040","first-page":"171","article-title":"Low dose naltrexone: side effects and efficacy in gastrointestinal disorders","volume":"14","author":"Ploesser","year":"2010","journal-title":"Int J Pharm Compd"}],"container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212440322009658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212440322009658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:13:27Z","timestamp":1761948807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212440322009658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S2212440322009658"],"URL":"https:\/\/doi.org\/10.1016\/j.oooo.2022.04.048","relation":{},"ISSN":["2212-4403"],"issn-type":[{"value":"2212-4403","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose naltrexone for treatment of burning mouth syndrome","name":"articletitle","label":"Article Title"},{"value":"Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oooo.2022.04.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}